HIV (human immunodeficiency virus) immune purifier

Abstract

An HIV (human immunodeficiency virus) immune purifier for the field of medical science is characterized in that a separator capable of separating plasma and blood cells is prepared, hybrid tumor macrophage cell lines retaining original macrophage properties and capable of infinitely growing are prepared by the aid of a hybridoma technique, CD4+T cell lines are built by exogenous gene transfection, specific molecular antibodies on surfaces of the CD4+T cell lines serve as growth stimulants for amplification, the prepared cell lines are distributed in a cell freezing medium, a container made of high-biocompatibility materials wraps the cell freezing medium to form the purifier, cell concentration reaches 80%, the purifier is sealed, cells are frozen and preserved for standby application in -196 DEG C liquid nitrogen for a long time, the macrophage cell lines and the CD4+T cell lines function in adsorbing HIV, the prepared purifier is combined with the separator and a control procedure in use, blood in extracorporeal circulation is divided into the plasma and the blood cells by the separator, the HIV in the plasma is filtered by the purifier, and then the plasma is converged with the blood cells and returned.

Description

technical field [0001] The invention relates to the preparation and application of an HIV immune purifier in the medical field, which is mainly used for the removal of plasma HIV from AIDS patients so as to achieve the purpose of treating AIDS. Background technique [0002] After HIV enters the human body, it is first swallowed by macrophages, but HIV quickly changes the acidic environment in certain parts of the macrophages and creates conditions suitable for its survival. Instead of being killed, HIV reproduces in them. Because CD4 is the receptor of HIV, the HIV that propagates in the macrophage passes through its envelope protein gp120 and with the help of gp41 (gp41 acts as a bridge, using its own hydrophobicity to mediate the fusion of the viral envelope and the cell membrane ) into CD4+ cells (cells, mononuclear macrophages, dendritic cells, etc.), proliferate rapidly in the cells, and produce 10 9 ~10 10 Virus particles, and continuously enter other normal and rege...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, if it wants to produce an immune effect, it must either activate the complement and mediate the ADCC effect to dissolve the cellular antigen, but HIV It is not a cellular antigen; either it attracts phagocytes to phagocytize and clear the antigen through chemotaxis, but HIV is protected and proliferates in the phagocytes instead; or the antibody binds to the antigen to neutralize it, making it lose its infectivity, but HIV antigens have many structures Mutations, often making it difficult for antibodies to recognize

[0004] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0007] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images